, Institut National du Cancer. Les cancers en France, 2017.
World Health Organization Classification of Tumours of the breast. World Heal Organ Classif tumours, Organ. Classif. tumours, p.240, 2012. ,
Évolution de la classification des cancers du sein, Biol Aujourdhui, vol.208, issue.4, pp.251-260, 2014. ,
Female patients with breast carcinoma age 30 years and younger have a poor prognosis, Cancer Interdiscip Int J Am Cancer Soc, vol.92, issue.10, pp.2523-2531, 2001. ,
Breast cancer in young women: clinicopathological features and biological specificity, Breast, vol.12, issue.4, pp.247-50, 2003. ,
Breast cancer diagnosis in women? 40 versus 50 to 60 years: increasing size and stage disparity compared with older women over time, Ann Surg Oncol, vol.13, issue.8, pp.1072-1079, 2006. ,
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer, vol.63, issue.1, pp.181-188, 1989. ,
The effect of tumor size and lymph node status on breast carcinoma lethality, Cancer Interdiscip Int J Am Cancer Soc, vol.98, issue.10, pp.2133-2176, 2003. ,
Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer, Int J Oncol, vol.22, issue.3, pp.697-704, 2003. ,
Annual hazard rates of recurrence for breast cancer after primary therapy, J Clin Oncol, vol.14, issue.10, pp.2738-2784, 1996. ,
, J. Extending Survival with Chemotherapy in Metastatic Breast Cancer. Oncologist, vol.10, issue.suppl_3, pp.20-29, 2005.
Annual hazard rates of recurrence for breast cancer during 24 years of followup: results from the international breast cancer study group trials I to V, J Clin Oncol, vol.34, issue.9, p.927, 2016. ,
De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype ,
, Clin Exp Metastasis, vol.34, issue.8, pp.457-65, 2017.
Metastatic behavior of breast cancer subtypes, J Clin Oncol, vol.28, issue.20, pp.3271-3278, 2010. ,
Cancer treatment and survivorship statistics, CA Cancer J Clin, vol.64, issue.4, pp.252-71, 2014. ,
, Breast cancer. Lancet, vol.6736, issue.16, pp.1134-50, 2016.
Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, A Cancer J Clin, vol.67, issue.4, pp.290-303, 2017. ,
Prognostic value of histologic grade nuclear components of ,
An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas, Cancer, vol.64, issue.9, pp.1914-1935, 1989. ,
Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems ,
, Anticancer Res, vol.18, issue.1B, pp.571-577, 1998.
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J Clin Oncol, vol.28, issue.16, pp.2784-95, 2010. ,
Predictive markers in breast cancer: An update on ER and HER2 testing and reporting, Semin Diagn Pathol, vol.32, issue.5, pp.362-371, 2015. ,
Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, Breast J, vol.15, issue.6, pp.593-602, 1999. ,
Untangling the ErbB signalling network, Nat Rev Mol cell Biol, vol.2, issue.2, p.127, 2001. ,
Molecular classification of breast cancer: what the pathologist needs to know, Pathology, vol.49, issue.2, pp.111-120, 2017. ,
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (80-), vol.235, pp.177-82, 1987. ,
Clinicopathological classification and traditional prognostic indicators of breast cancer, Int J Clin Exp Pathol, vol.8, issue.7, pp.8500-8505, 2015. ,
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, vol.353, issue.16, pp.1673-1684, 2005. ,
Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up ,
, Histopathology, vol.24, issue.1, pp.41-48, 1994.
uPA/PAI-1: Un outil d'individualisation de la prise en charge des cancers du sein. Biologie, implications cliniques et méthodes de dosage, Bull Cancer, vol.97, issue.3, pp.341-349, 2010. ,
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci, vol.98, pp.10869-10874, 2001. ,
, Faculté de médecine d'Angers. (page consultée le 01/09/19). Laboratoire d'hématologie du CHU d'Angers
Bone marrow involvement by metastatic solid tumors, Gujarat Med J, vol.69, issue.2, pp.54-61, 2014. ,
Symptomatic Bone Marrow Involvement in Breast Cancer -Clinical Presentation, Treatment, and Prognosis : A Single Institution Review of 22 Cases, Anticancer Res, vol.31, issue.11, pp.4025-4055, 2011. ,
Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer, J Clin Oncol, vol.21, issue.18, pp.3469-78, 2003. ,
,
, Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases, Asian Pacific J Cancer Prev, vol.15, issue.1, pp.61-68, 2014.
A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer, N Engl J Med, vol.353, pp.793-802, 2005. ,
Traitement du cancer du sein métastatique. Le cancer du sein, pp.209-234, 2007. ,
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment, Curr Cardiol Rev, vol.7, issue.4, pp.214-234, 2011. ,
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer, J Clin Oncol, vol.23, issue.24, pp.5542-5551, 2005. ,
Taxanes for the treatment of metastatic breast cancer, Breast Cancer Basic Clin Res, vol.6, issue.1, pp.159-71, 2012. ,
Weekly Paclitaxel for Metastatic Breast Cancer in Patients Previously Exposed to Paclitaxel, J Cancerol, vol.2, pp.75-84, 2015. ,
Weekly paclitaxel-An effective treatment for advanced breast cancer ,
, Anticancer Res, vol.33, issue.6, pp.2623-2631, 2013.
Update of the GEFPICS'recommendations for HER2 status determination in breast cancers in France, Ann Pathol, vol.30, issue.5, pp.357-73, 2010. ,
Recommandations pour l'évaluation immunohistochimique des récepteurs hormonaux sur coupes en paraffine dans les carcinomes mammaires Mise à jour 1999, Ann Pathol, 1999. ,
, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE).v.5.0. Natl Institutes Heal Natl Cancer Institute, vol.46
Bone marrow metastasis of solid tumors : Clinicopathological evaluation of 73 cases ,
, Turkish J Cancer, vol.37, issue.3, pp.85-93, 2007.
Variables predictive of bone marrow metastasis, Cancer, vol.42, issue.5, pp.2373-2381, 1978. ,
Prognostic Evaluation of Breast Cancer Patients with Evident Bone Marrow Metastasis, Breast J, vol.20, issue.3, pp.279-87, 2014. ,
Metastatic Bone Marrow Tumors: Study of Nine Cases and Review of the Literature, J Blood Disord Transfus, vol.02, issue.110, p.2, 2011. ,
Metastatic stem cells: sources, niches, and vital pathways, Cell Stem Cell, vol.14, issue.3, pp.306-327, 2014. ,
Metastasis Dormancy in Estrogen Receptor -Positive Breast Cancer, Clin Cancer Res, vol.19, issue.23, pp.6389-97, 2013. ,
Bone metastasis and the metastatic niche, J Mol Med, vol.93, issue.11, pp.1203-1215, 2015. ,
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity, Clin Cancer Res, vol.12, issue.20, pp.6243-50, 2006. ,
Invasive lobular carcinoma of the breast : A special histological type compared with invasive ductal carcinoma, PLoS One, vol.12, issue.9, p.182397, 2017. ,
A case of recurrent breast cancer with bone marrow metastasis treated with weekly paclitaxel therapy, Cancer Chemother, vol.35, issue.9, pp.1611-1614, 2008. ,
, Cancer Chemother, vol.39, issue.1, pp.99-101, 2012.
Low-dose capecitabine in breast cancer patients with symptomatic bone marrow infiltration: A case study, Anticancer Res, vol.28, pp.539-581, 2008. ,
Hormonal Treatment for Symptomatic Bone Marrow Metastasis in Breast Cancer Patients. MAEDICA a, J Clin Med, vol.13, issue.3, pp.238-278, 2018. ,
Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer, Gynecol Endocrinol, vol.34, issue.4, pp.286-295, 2018. ,
The role of myelofibrosis in malignant leukoerythroblastosis, Cancer, vol.51, issue.2, pp.308-319, 1983. ,
,
, Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors : palbociclib and ribociclib. The Breast, vol.35, pp.1-7, 2017.
,
, Hematological adverse effects in breast cancer patients treated with cyclindependent kinase 4 and 6 inhibitors : a systematic review and meta-analysis, Breast Cancer, vol.25, issue.1, pp.17-27, 2018.
MONARCH 3 : Abemaciclib As Initial Therapy for Advanced Breast Cancer, J Clin Oncol, issue.32, p.35, 2017. ,
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib, Semin Oncol, vol.44, issue.6, pp.395-403, 2017. ,
Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Modeling and Simulation Approach, vol.57, pp.1159-1173, 2017. ,
,
, Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies, vol.22, pp.2000-2008, 2016.